Across TCGA pan-cancer cohorts, BAHD1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BAHD1 data layer compared with 21 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BAHD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BAHD1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.
LUAD and LSCC are the cancer types where BAHD1 mass-spec protein most reproducibly stratifies survival.